LAKE FOREST, CALIFORNIA — Sonorous Neurovascular has enrolled the first Canadian patient in its international B-SILENT clinical study evaluating the investigational BosSTENT for the treatment of debilitating pulsatile tinnitus associated with symptomatic cerebral venous sinus stenosis. The enrollment took place at The Ottawa Hospital under principal investigator Dr....
Continue reading at Hearing Health Matters
✦ The floor
Discussion
Signed responses from readers of the wire.
No actionable change; the BosSTENT device is investigational and the B-SILENT trial is still enrolling — audiologists should monitor results but cannot yet apply this to practice.
Pulsatile tinnitus linked to narrowed brain blood vessels (cerebral venous sinus stenosis) has very limited treatment options, and a dedicated implant trial could open a new interventional pathway if results are positive.
- 01Sonorous Neurovascular has enrolled the first Canadian patient in the B-SILENT international clinical study.
- 02B-SILENT evaluates the BosSTENT, an investigational device targeting pulsatile tinnitus caused by cerebral venous sinus stenosis (a narrowed brain vein).
- 03The study is international in scope, extending enrollment beyond the US.
- 04BosSTENT is not yet approved; this is an early-phase clinical trial milestone.
- 05Pulsatile tinnitus from venous sinus stenosis is a distinct, vascular subtype of tinnitus with few established interventions.
The BosSTENT device is being evaluated as a treatment for pulsatile tinnitus caused by cerebral venous sinus stenosis.
press releaseunclearSonorous Neurovascular has enrolled the first Canadian patient in the B-SILENT study.
press releasesupported